195 related articles for article (PubMed ID: 37858219)
1. ALKBH5 enhances lipid metabolism reprogramming by increasing stability of FABP5 to promote pancreatic neuroendocrine neoplasms progression in an m6A-IGF2BP2-dependent manner.
Chen J; Ye M; Bai J; Gong Z; Yan L; Gu D; Hu C; Lu F; Yu P; Xu L; Wang Y; Tian Y; Tang Q
J Transl Med; 2023 Oct; 21(1):741. PubMed ID: 37858219
[TBL] [Abstract][Full Text] [Related]
2. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
[TBL] [Abstract][Full Text] [Related]
3. RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A-YTHDF2-dependent manner.
Shen D; Lin J; Xie Y; Zhuang Z; Xu G; Peng S; Tang G; Bai L; Zhu M; Zhang Y; Huang Z; Wang P; Liu X; Huang M; Luo Y; Wang X; Yu H
Clin Transl Med; 2023 May; 13(5):e1279. PubMed ID: 37203239
[TBL] [Abstract][Full Text] [Related]
4. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.
Yang Z; Cai Z; Yang C; Luo Z; Bao X
EBioMedicine; 2022 Jun; 80():104019. PubMed ID: 35490460
[TBL] [Abstract][Full Text] [Related]
5. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma.
Jin S; Li M; Chang H; Wang R; Zhang Z; Zhang J; He Y; Ma H
Mol Cancer; 2022 Apr; 21(1):97. PubMed ID: 35395767
[TBL] [Abstract][Full Text] [Related]
6. ALKBH5 inhibits the SIRT3/ACC1 axis to regulate fatty acid metabolism via an m6A-IGF2BP1-dependent manner in cervical squamous cell carcinoma.
Zhen L; Pan W
Clin Exp Pharmacol Physiol; 2023 May; 50(5):380-392. PubMed ID: 36705046
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K/AKT/mTOR pathway to promote the progression of pancreatic neuroendocrine neoplasms.
Gu D; Ye M; Zhu G; Bai J; Chen J; Yan L; Yu P; Lu F; Hu C; Zhong Y; Liu P; He Q; Tang Q
J Transl Med; 2024 Jan; 22(1):93. PubMed ID: 38263056
[TBL] [Abstract][Full Text] [Related]
8. Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis in colorectal cancer.
Ye M; Chen J; Lu F; Zhao M; Wu S; Hu C; Yu P; Kan J; Bai J; Tian Y; Tang Q
Cell Biosci; 2023 Aug; 13(1):148. PubMed ID: 37580808
[TBL] [Abstract][Full Text] [Related]
9. Suppression of m6A mRNA modification by DNA hypermethylated ALKBH5 aggravates the oncological behavior of KRAS mutation/LKB1 loss lung cancer.
Zhang D; Ning J; Okon I; Zheng X; Satyanarayana G; Song P; Xu S; Zou MH
Cell Death Dis; 2021 May; 12(6):518. PubMed ID: 34016959
[TBL] [Abstract][Full Text] [Related]
10. ALKBH5 activates FAK signaling through m6A demethylation in
Sun R; Yuan L; Jiang Y; Wan Y; Ma X; Yang J; Sun G; Zhou S; Wang H; Qiu J; Zhang L; Cheng W
Theranostics; 2023; 13(2):833-848. PubMed ID: 36632222
[No Abstract] [Full Text] [Related]
11. Loss of m6A demethylase ALKBH5 promotes post-ischemic angiogenesis via post-transcriptional stabilization of WNT5A.
Zhao Y; Hu J; Sun X; Yang K; Yang L; Kong L; Zhang B; Li F; Li C; Shi B; Hu K; Sun A; Ge J
Clin Transl Med; 2021 May; 11(5):e402. PubMed ID: 34047466
[TBL] [Abstract][Full Text] [Related]
12. HPV E7-drived ALKBH5 promotes cervical cancer progression by modulating m6A modification of PAK5.
Huo FC; Zhu ZM; Du WQ; Pan YJ; Jiang X; Kang MJ; Liu BW; Mou J; Pei DS
Pharmacol Res; 2023 Sep; 195():106863. PubMed ID: 37480971
[TBL] [Abstract][Full Text] [Related]
13. m6A methylation regulates hypoxia-induced pancreatic cancer glycolytic metabolism through ALKBH5-HDAC4-HIF1α positive feedback loop.
Liu X; Feng M; Hao X; Gao Z; Wu Z; Wang Y; Du L; Wang C
Oncogene; 2023 Jun; 42(25):2047-2060. PubMed ID: 37149664
[TBL] [Abstract][Full Text] [Related]
14. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential.
Qu J; Yan H; Hou Y; Cao W; Liu Y; Zhang E; He J; Cai Z
J Hematol Oncol; 2022 Jan; 15(1):8. PubMed ID: 35063010
[TBL] [Abstract][Full Text] [Related]
15. Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response.
Yu F; Wei J; Cui X; Yu C; Ni W; Bungert J; Wu L; He C; Qian Z
Nucleic Acids Res; 2021 Jun; 49(10):5779-5797. PubMed ID: 34048572
[TBL] [Abstract][Full Text] [Related]
16. Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification.
Hu Y; Gong C; Li Z; Liu J; Chen Y; Huang Y; Luo Q; Wang S; Hou Y; Yang S; Xiao Y
Mol Cancer; 2022 Feb; 21(1):34. PubMed ID: 35114989
[TBL] [Abstract][Full Text] [Related]
17. ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner.
Wang W; Huang Q; Liao Z; Zhang H; Liu Y; Liu F; Chen X; Zhang B; Chen Y; Zhu P
Exp Hematol Oncol; 2023 Jan; 12(1):1. PubMed ID: 36609413
[TBL] [Abstract][Full Text] [Related]
18. The N6-Methyladenosine Regulator
Zhao Y; Sun J; Jin L
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555463
[TBL] [Abstract][Full Text] [Related]
19. FABP5 suppresses colorectal cancer progression via mTOR-mediated autophagy by decreasing FASN expression.
Ye M; Hu C; Chen T; Yu P; Chen J; Lu F; Xu L; Zhong Y; Yan L; Kan J; Bai J; Li X; Tian Y; Tang Q
Int J Biol Sci; 2023; 19(10):3115-3127. PubMed ID: 37416772
[TBL] [Abstract][Full Text] [Related]
20. USF1-mediated ALKBH5 stabilizes FLII mRNA in an m6A-YTHDF2-dependent manner to repress glycolytic activity in prostate adenocarcinoma.
Fu D; Si Q; Yu C; Han Z; Zang L
Mol Carcinog; 2023 Nov; 62(11):1700-1716. PubMed ID: 37493109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
